Beauty Health (NASDAQ:SKIN) Trading 5.4% Higher

The Beauty Health Company (NASDAQ:SKIN) traded up 5.4% during mid-day trading on Tuesday . The company traded as high as $4.35 and last traded at $4.33. 143,832 shares changed hands during trading, a decline of 95% from the average session volume of 2,901,702 shares. The stock had previously closed at $4.11.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. TD Cowen lifted their price target on shares of Beauty Health from $2.50 to $4.00 and gave the company a “market perform” rating in a research note on Wednesday, March 13th. Piper Sandler reaffirmed an “underweight” rating and issued a $3.00 price objective (up from $2.00) on shares of Beauty Health in a research report on Wednesday, March 13th. DA Davidson reiterated a “buy” rating and set a $5.00 target price on shares of Beauty Health in a report on Friday, March 15th. Canaccord Genuity Group boosted their price target on Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a report on Thursday, March 14th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $4.00 price objective (up from $3.00) on shares of Beauty Health in a research report on Wednesday, March 13th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Beauty Health has a consensus rating of “Hold” and an average target price of $6.50.

Beauty Health Price Performance

The company has a quick ratio of 5.28, a current ratio of 6.07 and a debt-to-equity ratio of 12.43. The company has a fifty day moving average price of $3.33 and a two-hundred day moving average price of $3.75.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. The firm had revenue of $96.80 million during the quarter, compared to the consensus estimate of $87.22 million. During the same period last year, the company earned $0.03 earnings per share. The business’s revenue was down 1.3% compared to the same quarter last year. As a group, sell-side analysts forecast that The Beauty Health Company will post -0.12 EPS for the current fiscal year.

Institutional Trading of Beauty Health

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Beauty Health by 16.7% during the 1st quarter. JPMorgan Chase & Co. now owns 109,834 shares of the company’s stock worth $1,854,000 after purchasing an additional 15,695 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its position in Beauty Health by 121.6% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 26,102 shares of the company’s stock worth $441,000 after buying an additional 14,323 shares during the last quarter. HighTower Advisors LLC bought a new stake in Beauty Health in the first quarter valued at approximately $199,000. Citigroup Inc. lifted its position in shares of Beauty Health by 15.0% in the first quarter. Citigroup Inc. now owns 145,292 shares of the company’s stock valued at $2,452,000 after buying an additional 18,985 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its stake in shares of Beauty Health by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 48,780 shares of the company’s stock worth $823,000 after acquiring an additional 17,710 shares during the period. Institutional investors and hedge funds own 93.26% of the company’s stock.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.